Diabetic nephropathy: Time to withhold development and progression - A review
Reads0
Chats0
TLDR
In this article, the authors highlight the recent advances in understanding the pathogenesis, diagnosis, the established and the potential renoprotective therapeutic agents that would prevent the development or the progression of diabetic nephropathy.About:
This article is published in Journal of Advanced Research.The article was published on 2017-07-01 and is currently open access. It has received 39 citations till now. The article focuses on the topics: Diabetic nephropathy.read more
Citations
More filters
Journal ArticleDOI
A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.
TL;DR: In this article, the authors discuss the potential of bi-and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat Type 2 diabetes.
Journal ArticleDOI
Double or hybrid diabetes: A systematic review on disease prevalence, characteristics and risk factors.
TL;DR: The worldwide prevalence of double or hybrid diabetes, its main physiological characteristics, including beta-cell autoimmunity, insulin resistance, and cardiovascular disease, the main risk factors of developing DD, mainly genetics, obesity and lifestyle choices, as well as potential treatments, such as insulin titration, metformin and behavioural modifications are discussed.
Journal ArticleDOI
Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation.
Rayne Gomes Amorim,Glaucevane da Silva Guedes,Sandra Mary Lima Vasconcelos,Juliana Célia de Farias Santos +3 more
TL;DR: The present study presents an update on metabolic pathways that involve redox imbalance and inflammation induced by chronic exposure to hyperglycemia in the pathogenesis of diabetic kidney disease.
Journal ArticleDOI
Assessing urinary levels of IL-18, NGAL and albumin creatinine ratio in patients with diabetic nephropathy
Taqwaa Sueud,Najah R. Hadi,Raed Abdulameer,Dina A. Jamil,Hayder A. Al-Aubaidy,Hayder A. Al-Aubaidy +5 more
TL;DR: It is concluded that the urinary ACR is a more accurate individual biomarker of DN when compared to both NGAL and IL-18.
References
More filters
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
TL;DR: In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.
Journal ArticleDOI
Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus
TL;DR: Elevated levels of microalbuminuria strongly predict the development of clinical diabetic nephropathy, and these levels of AER are potentially reversible, and their detection and treatment may prevent diabetic renal disease.
Journal ArticleDOI
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney,Bruce A. Perkins,Nima Soleymanlou,Maria Maione,Vesta Lai,Alana Lee,Nora M. Fagan,Hans-Juergen Woerle,Odd Erik Johansen,Uli C. Broedl,Maximilian von Eynatten +10 more
TL;DR: Short-term treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjects with T1D, likely by affecting tubular-glomerular feedback mechanisms.
Journal ArticleDOI
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study
TL;DR: Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria slows progression to nephropathy, and progression of retinopathy and autonomic neuropathy.